奈非那韦耐性细胞株对其它抗艾滋病药、抗肿瘤药的交叉耐性及多药耐药表型分析Cross - resistance of Nelflnavir - resistant MT - 4 Cell Lines to Other Anti - AIDS Drugs and Antitumor Agents and Flow Cytometric Analysis of Multiple Drug Resistance Phenotype
修文琼,冈本■佳,下■敏,马场昌■
摘要(Abstract)：
目的 在体外进行细胞对抗艾滋病药产生耐性的相关因子研究。方法 通过将成人T细胞白血病细胞系MT-4培养于含有奈非那韦浓度不断增加直至14μmol/L的培养液中培养30天以获得耐奈非那韦的亚系细胞株MT-4rN。用细胞增殖分析系统四唑嗡染色法测定存活细胞数并用流式细胞仪及荧光化合物罗丹明-123和P-糖蛋白阻遏物维拉帕米分析多药耐药蛋白P-gp的存在。结果 发现MT-4rN细胞对新近报道的抗艾滋病药K-37产生出比母本细胞多20倍的耐性。对其它抗肿瘤药的交叉耐性也有不同程度的提高。并且,耐性细胞的荧光密度在维拉帕米存在下有些不同,意味着P-gp在MT-4rN中的表达略有增多。结论 在用HIV-1蛋白酶抑制物奈非那韦作用后,MT-4细胞对其它抗艾滋病药及抗肿瘤药产生了交叉耐性并且多药耐药蛋白P-gp的表达有所增加。
关键词(KeyWords)： 奈非那韦; 交叉耐性; 抗艾滋病药; 抗肿瘤药 ; 多药耐药蛋白;P-gp
基金项目(Foundation): 日中医学协会(?)川医学奖学金的资助
作者(Author): 修文琼,冈本■佳,下■敏,马场昌■
参考文献(References)：
- 1 Patick A K, Mo H, Markowitz M, et al. Antiviral and resistance studios of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother, 1996, 40:292 -297
- 2 Berger E A, Moss B, Pastan I. Reconsidering targeted toxins to eliminate HIV infection: You gotta have HAART. Proc. Natl. Acad. Sci, 1998, USA 95,11 511-11 513
- 3 Baba M, Okamoto M, Kawamura M, et al. Inhibition of human im munodeficiency virus type I replication and cytokine production by flu-oroquinoline derivatives. Mol.Pharmacol, 1998, 53:1 097-1 103
- 4 Antonelli G, Turriziani O, Cianfriglia M, et al. Resistance of HIV - 1 to AZT might also involve the cellular expression of multidrug resistance P - glycoprotein.AIDS Res.Hum. Retroviruses, 1992, 8: 1 839 -1 844
- 5 Gottesman M M, How cancer ceils evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture (review ). Cancer Res, 1993,53:747-754
- 6 Ling V.P - glycoprotein and resistance to anticancer drugs. Cancer, 1992,69:2603-2609
- 7 Schuetz J D, Connelly M C, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside - based antiviral drugs.Nat.Mat.,1999,5:1 048-1 051
- 8 Ishiyama M. A highly water - solution disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta, 1997,44:1 299-1 305
- 9 Krishan A, Sauerteig A, Andritsch L, et al. Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia, 1997, 11: 1 138 -1 146
- 10 Agarwal R P, Wang W, Yo P, et al. Cross- resistance of dideoxycy-tidine- resistance cell lines to azidothymidine. Biochem. Pharmacol, 1999,58:1 603-1 608
- 11 Cinatl J. Jr., R. Kotchetkov, B. Gr schel, et al. Azidothymidine resistance of H9 human T ?cell lymphoma cells is associated with decreased sensitivity to antitumor agents and inhibition of apopto-sis.Jnt.J.Mol.Med., 1998,2:685-691
- 12 Wu S, X.Liu, M.M.Solorzano, et al.Development of zidovudine (AZT) resistant in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5' end of human TK gene. J Acquir. Immune. Defic. Syndr. Hum. Retrovirol., 1995, 8:1 -9